Paul Jeng
Stock Analyst at Guggenheim
(2.91)
# 2,945
Out of 4,491 analysts
25
Total ratings
54.5%
Success rate
7.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintained: Buy | $45 | $9.31 | +383.35% | 2 | Jun 2, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Buy | $54 | $37.82 | +42.78% | 7 | Jun 2, 2026 | |
| IMTX Immatics | Maintained: Buy | $19 | $9.91 | +91.82% | 5 | May 12, 2026 | |
| CHRS Coherus Oncology | Initiated Coverage: Buy | $12 | $1.61 | +647.66% | 1 | May 11, 2026 | |
| CNTX Context Therapeutics | Maintained: Buy | $5 | $0.621 | +705.15% | 4 | May 6, 2026 | |
| ADAG Adagene | Maintained: Buy | $10 | $3.93 | +154.45% | 4 | Apr 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $33.19 | - | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $4.08 | n/a | 1 | Jul 29, 2020 |
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Maintained: Buy
Price Target: $45
Current: $9.31
Upside: +383.35%
IDEAYA Biosciences
Jun 2, 2026
Maintained: Buy
Price Target: $54
Current: $37.82
Upside: +42.78%
Immatics
May 12, 2026
Maintained: Buy
Price Target: $19
Current: $9.91
Upside: +91.82%
Coherus Oncology
May 11, 2026
Initiated Coverage: Buy
Price Target: $12
Current: $1.61
Upside: +647.66%
Context Therapeutics
May 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.621
Upside: +705.15%
Adagene
Apr 6, 2026
Maintained: Buy
Price Target: $10
Current: $3.93
Upside: +154.45%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $33.19
Upside: -
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $4.08
Upside: n/a